ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0466

Assessment of Probability Scores to Predict Giant Cell Arteritis

Chadi Sargi1, Stephanie Ducharme-Benard2, Valerie Benard3, Rosalie-Selene Meunier4, Carolyn Ross5 and Jean-Paul Makhzoum6, 1University of Montreal, Laval, Canada, 2Hopital Sacre-Coeur, Montréal, QC, Canada, 3University of Montreal, Saint-Ambroise-de-Kildare, Canada, 4Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, 5University of Montreal, Montréal, QC, Canada, 6Hopital du Sacre-Coeur de Montreal, Montréal, QC, Canada

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis but remains challenging to diagnose. In the past years, many probability tools have been developed to predict the presence of GCA. Clinical prediction tools include the GCA probability score (GCAPS), the GCA prediction model (Ing Score) and the Bhavsar-Khalidi (BK) score. Color doppler ultrasound (CDUS) prediction scores include the halo count and halo score. The objective of this study is to assess and compare the performance of these probability tools to predict a final diagnosis of GCA.

Methods: A monocentric, prospective, observational study, with systematic data collection was conducted from April to December 2021. Consecutive patients referred to our tertiary CDUS Fast-Track clinic with a suspected new-onset GCA were included. CDUS of temporal and axillary arteries was performed by experimented GCA specialists using a Canon XarioTM 200 Platinum series with an 18L7 probe. Final diagnosis of GCA was determined by the treating physician. A second confirmation of the final diagnosis was performed by a vasculitis specialist (blinded to CDUS results), 3 months after the initial Fast-Track clinic consultation. Clinical probability scores were calculated once final diagnosis was confirmed using data systematically collected at the initial visit. ROC curves were assessed to determine the best cut-off values for each prediction score.

Results: 200 patients with a suspected new-onset GCA were included: 58 with confirmed GCA and 142 without GCA.

Using a cut-off value of 9.5 points as positive, the GCAPS showed a sensitivity (Se) of 98.3% and a specificity (Sp) of 62.9%. Only 1 patient with confirmed GCA had a GCAPS below 9.5. The Ing score showed a Se of 82.7% and a Sp of 62.7% when using an intermediate probability level (level 3) or more as positive. The BK score showed a Se of 87.9% and a Sp of 71.1% when considering a moderate score (level 2) or more as positive. As for CDUS, a halo count of 1 or more was found to have a Se of 96.6% and a Sp of 97.9%, whereas a total halo score of 2 or more had a Se of 96.6% and a Sp of 84.5%.

The value of a concordant combination between clinical score and CDUS halo count (positive clinical-CDUS combination, or negative clinical-CDUS combination) was assessed to predict or exclude GCA. A GCAPS-CDUS concordant combination showed a Se of 100%, Sp of 97.7%, positive predictive value (PPV) of 96.5% and a negative predictive value (NPV) of 100%. A concordant Ing score-CDUS combination showed a Se of 97.9%, Sp of 97.8%, PPV of 95.9% and NPV of 98.8%. A concordant BK score-CDUS combination showed a Se of 98.0%, Sp of 98%, PPV of 96.2% and a NPV of 99.0%.

Conclusion: In our prospective cohort, we found that the GCAPS had the highest sensitivity, whereas the BK score had the highest specificity. Both scores are easy to calculate and use. The CDUS halo score and halo count both showed high sensitivity and specificity. Using a combination of a clinical score with CDUS halo count provided an accurate GCA prediction method which may be used in the setting of GCA Fast-Track clinics.


Disclosures: C. Sargi, None; S. Ducharme-Benard, None; V. Benard, None; R. Meunier, None; C. Ross, None; J. Makhzoum, None.

To cite this abstract in AMA style:

Sargi C, Ducharme-Benard S, Benard V, Meunier R, Ross C, Makhzoum J. Assessment of Probability Scores to Predict Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/assessment-of-probability-scores-to-predict-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-probability-scores-to-predict-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology